ResMed to continue ascent in November

This piece will digest ResMed. I will analyze why it could be a much better year for ResMed shareholders. This firm Piotroski F Score is 3 - Frail. Considering 30-days investment horizon, ResMed is expected to generate 1.45 times more return on investment than the market. However, the company is 1.45 times more volatile than its market benchmark. It trades about 0.09 of its potential returns per unit of risk. The market is currently generating roughly 0.0 per unit of risk. ResMed holds recent Real Value of $144.46 per share. The prevailing price of the company is $144.26. At this time the company appears to be fairly valued. This module determines value of ResMed from analyzing the company fundamentals such as Return On Equity of 19.59 , Operating Margin of 30.18  and Shares Outstanding of 143.67 M as well as examining its technical indicators and Probability Of Bankruptcy. In general, we support investing in undervalued entities and to dispose of overvalued entities since at some point stocks prices and their ongoing real values will merge together.
Published over a year ago
View all stories for ResMed | View All Stories
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.

Reviewed by Raphi Shpitalnik

RESMED INC has roughly 147.13 M in cash with 423.41 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.02. ResMed dividends can provide a clue to current valuation of the stock. The firm one year expected dividend income is about $0.72 per share. The company has Net Profit Margin of 15.52 % which may imply that it executes well on its competitive polices and has a good control over its expenditures and variable costs. This is very large. In the same way, it shows Net Operating Margin of 30.18 % which entails that for every 100 dollars of revenue it generated 0.3 of operating income.
Investing in ResMed, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding ResMed along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of ResMed's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as ResMed. Your research has to be compared to or analyzed against ResMed's peers to derive any actionable benefits. When done correctly, ResMed's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in ResMed Inc.

How important is ResMed's Liquidity

ResMed financial leverage refers to using borrowed capital as a funding source to finance ResMed Inc ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. ResMed financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to ResMed's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of ResMed's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between ResMed's total debt and its cash.

ResMed Gross Profit

ResMed Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing ResMed previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show ResMed Gross Profit growth over the last 10 years. Please check ResMed's gross profit and other fundamental indicators for more details.

ResMed Correlation with Peers

Investors in ResMed can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in ResMed Inc. Diversification will allow for the same portfolio return with reduced risk. The correlation table of ResMed and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities ResMed is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage. Please check volatility of ResMed for more details

Breaking it down

The modest gains experienced by current holders of ResMed has created some momentum for investors as it was traded today as low as 141.29 and as high as 147.37 per share. The company executives have been quite successful with maneuvering the stock at opportune times to take advantage of all market conditions in September. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 2.1357. The current volatility is consistent with the ongoing market swings in September 2019 as well as with ResMed unsystematic, company specific events. ResMed preserves 4.76  of probability of bankruptcy. ResMed is trading at 144.26 which is 12.94% increase. Started trading at 144.26. ResMed Investments is rather stable at the moment. Also, ResMed Shareholders Equity USD is increasing over the last 5 years.
 2015 2018 2019 (projected)
ResMed Consolidated Income 352,409,000  317,168,100  237,554,158 
ResMed Direct Expenses 772,216,000  1,069,987,000  844,304,699 
All things considered, our research shows that ResMed is very steady with very low chance of bankruptcy in the next two years. Our up-to-date buy-hold-sell recommendation on the firm is Strong Buy.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of ResMed Inc. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com